Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.
about
Development of bisphosphonates.The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statinsInflammatory eye reactions with bisphosphonates and other osteoporosis medications: what are the risks?Harnessing the power of Vδ2 cells in cancer immunotherapyStructural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesisDesign, Synthesis, Calorimetry, and Crystallographic Analysis of 2-Alkylaminoethyl-1,1-bisphosphonates as Inhibitors of Trypanosoma cruzi Farnesyl Diphosphate SynthaseReview of risedronate in the treatment of osteoporosisA novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitroInhibition of farnesylpyrophosphate synthase prevents angiotensin II-induced hypertrophic responses in rat neonatal cardiomyocytes: involvement of the RhoA/Rho kinase pathwaySynthesis, structure and assessment of the cytotoxic properties of 2,5-dimethylazaferrocenyl phosphonates.Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.Water-soluble polymer-drug conjugates for combination chemotherapy against visceral leishmaniasis.Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasisLysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.A chemical genomic study identifying diversity in cell migration signaling in cancer cells.Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.Molecular bases of progeroid syndromes.Promising therapeutic targets for antileishmanial drugs.Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures.The Roles of Small GTPases in Osteoclast BiologyEffects of D-003 (10 mg/day) on bone mineral density of the lumbar spine and femoral neck in postmenopausal women: a randomized, double-blinded study.Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cellsMinodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.Structural characterization of substrate and inhibitor binding to farnesyl pyrophosphate synthase from Pseudomonas aeruginosa.Cloning and characterization of farnesyl pyrophosphate synthase from the highly branched isoprenoid producing diatom Rhizosolenia setigera.Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw.Bone-targeted agents in the treatment of lung cancer.RNA therapeutics targeting osteoclast-mediated excessive bone resorption.The effects of zoledronate on the survival and function of human osteoblast-like cellsFarnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women.Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.Risedronate for prevention and treatment of osteoporosis in postmenopausal women.Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-AnalysisInhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid.Equilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats.The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells.New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects.
P2860
Q21195188-87B4CF40-A34B-47D0-A7BB-746C1DD84F8BQ24684244-A0B3A61F-7462-4C02-BD79-D923C195B6C9Q27024738-2AD269E5-C2B3-47A1-BBAE-FB343ADB5239Q27027547-3A6DA6AF-0C15-4D75-B5FF-57BEF4680B42Q27642782-73EB3318-1DA3-45C5-937B-9F7B2CCCDB21Q27681260-A7527AA3-DE62-414F-A0BE-A3FDB539D2F9Q28192294-77F264D6-24E8-4A1B-9267-94AF23F5C588Q28247578-DDD6BE38-BFF2-4BF4-B34A-0DF41B9F6510Q28577117-F65B1EC0-CB03-4A02-8A74-8CE80962CFA1Q31029121-465009EA-81FF-4CC9-B1F6-BEC18CDC4801Q33236626-A2494BE1-9215-4E76-B516-05A146778540Q33823803-1C81A8CE-E93C-4732-97AF-B709913B29BEQ33920919-8FB1EE1F-7D37-491B-A100-E62417D5A09DQ34009569-2F954AE2-1558-48E8-98E6-7D116C965471Q34024176-A8832093-BC98-4946-849D-1B0C29B277D4Q34395222-57D70316-4019-4A82-B95B-94AC5B96EFAFQ34472225-4BD543D8-8591-4039-8FC4-06A7E342DF32Q34480630-FB8838DA-E6AB-4E05-ADDB-901554FBDC6AQ34567458-5AB545EB-73AE-42E1-9DC3-A6B3547202ADQ34837180-E80051AA-FB6A-4DBA-9035-098C345CF687Q34890347-EC8F932C-2D40-4A7C-B3BD-72EEC27A21A0Q34975336-683D4BB4-DBA7-442B-B463-0D19C6046A6CQ35033570-3BDC7884-43A5-472F-AA10-7BC60548686DQ35043887-906D6375-FD7A-4F86-BC2C-2262C42A439BQ35103539-E0C8858B-A6D7-4579-BC12-03BFDF9482DFQ35575151-D353B0A7-0181-4EBD-860D-62B6E7088B38Q35633672-1C7D5799-686F-4D4A-869B-8E9294D60163Q35682511-378EAA37-DF95-4B87-8AFB-37D60C246F71Q35780792-51630A68-9D28-4828-9280-A89777DE3D40Q35800463-D2C4FCE3-9F2A-4E6D-B8CC-D537EE1249D5Q35842418-5988E7B5-293F-4822-B34B-F1072FFDCF40Q35949189-C0E5D758-C4E3-40DF-A4B8-ABAE5910F726Q35987738-0B4FAF05-B40D-40DE-9A57-9795D67421EAQ36082078-2A67F0F5-EB54-4ACD-AAE1-F820BC9F95AEQ36194583-3D3483E8-7EB3-4C50-AF37-7B96404B4831Q36206819-F081942B-3E5B-4B8C-B720-B15FB35BED02Q36459367-92207C1A-5673-43E3-80E3-B8D37EA90A9BQ36553571-0EE3837A-A1C5-4CB7-8DF4-CB0EA7688E07Q36644394-FA58985A-8015-4277-B067-F747CD011ED4Q36648924-4CDB6DC5-7A28-4EF0-9CD7-598800680DC2
P2860
Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Farnesyl pyrophosphate synthas ...... en-containing bisphosphonates.
@en
Farnesyl pyrophosphate synthas ...... en-containing bisphosphonates.
@nl
type
label
Farnesyl pyrophosphate synthas ...... en-containing bisphosphonates.
@en
Farnesyl pyrophosphate synthas ...... en-containing bisphosphonates.
@nl
prefLabel
Farnesyl pyrophosphate synthas ...... en-containing bisphosphonates.
@en
Farnesyl pyrophosphate synthas ...... en-containing bisphosphonates.
@nl
P2093
P356
P1476
Farnesyl pyrophosphate synthas ...... en-containing bisphosphonates.
@en
P2093
P304
P356
10.1006/BBRC.1999.1499
P407
P577
1999-10-01T00:00:00Z